Google+ Facebook Twitter Twitter

SARS-COV-2 spike mutations and infectivity

Researchers at the Francis Crick Institute have compared the original SARS-CoV-2 spike protein with a mutated version that arose last spring. 

They have found structural differences that could help to explain why the mutated version remains the dominant form circulating in all recent variants of concern, such as the UK and South African strains. 

As SARS-CoV-2 has evolved, mutations impacting the structure of the viral spike protein have affected how it binds to and infects cells. 

These changes have had huge implications for the spread of disease as new variants dominate, in part due to changes in the fitness of the virus. 

The scientists used electron cryomicroscopy to gain detailed images of a variant form of SARS-CoV-2 spike protein. They then compared this with a previous study examining the original “Wuhan” form of the virus. The variant spike, called G614, is a mutated version that first arose around spring 2020 and is now the dominant version of the spike in circulation, including in the recently identified variants of concern.

By analysing their structures, the researchers found that the mutated G614 spike would more easily bind to human cells due to its open and flexible structure. While the original spike adopted a generally more closed form, they observed that the mutant spike could adopt a greater number of open and erect conformations, which would prime the protein for binding to the human cell receptor ACE2.



Related Articles

Rethink the lateral flow test roll-out?

Professor Iain Buchan argues that lateral flow tests have been misunderstood and are a useful tool in the fight against COVID-19.

Diagnostic legislation changes

Pathology Quality Manager Jessica Dixon looks at safety and quality assurance practices in relation to expanded testing due to the pandemic.

First test for all known human coronaviruses

Scientists at the Centre for Infection and Immunity (CII) at Columbia University Mailman School of Public Health and Sun Yat-sen University in China have set the stage for the development of highly sensitive antibody tests for infection with all known human coronaviruses, including new variants of SARS-CoV-2.